Human VEGF held a market share of over 60% in 2021, with a value of US$ 117.4 Mn, according to Persistence Market Research. By the end of 2021, the market for growth factors had 17.2% of its revenue from VEGF.At the end of 2021, the global Vascular Endothelial Growth Factors (VEGF) Market was valued at US$ 195.4 Mn, with a projected CAGR of 10.7% over the next ten years, indicating a very progressive market expansion. According to a thorough industry assessment, the market will grow to a US$ 590.6 Mn valuation by the end of 2032.
Request for Free Sample Copy@ https://www.persistencemarketresearch.com/samples/33129
Over the previous nine years, the global VEGF market grew at a CAGR of 6.8%. (2012-2021). Renovascular disease (RVD) and coronary artery disease are becoming more common, which is increasing demand for alternatives to current therapies and driving growth in the global vascular endothelial growth factor market.
The development of novel approaches for treating diseases, as well as gaining encouraging insights into the protein structure, have increased research activities examining the benefits of growth factors in the onset of disease. VEGF molecules have a variety of applications.
What Business Opportunities Exist for VEGF Manufacturers?
Treatment of Peripheral Vascular Diseases with VEGF
Recently, the angiogenic effects of co-delivering the genes for nerve growth factor and VEGF in cells and a mouse model of hind limb ischemia were assessed (March 2022). The results showed that VEGF and nerve growth factor gene co-delivery nanoparticles boosted HUVEC movement, tube formation, proliferation, and H2O2 damage resistance while simultaneously increasing VEGF and nerve growth factor co-expression.
Additionally, it has been discovered that VEGF and nerve growth factor gene co-delivery nanoparticles enhance blood perfusion, promote VEGF and nerve growth factor expression, and boost pericyte vascular coverage.
Request For Customization@ https://www.persistencemarketresearch.com/request-customization/33129
Competitive Landscape
Leading VEGF providers are aiming at acquisitions and collaborations to expand their product portfolios and sales footprint across the globe.
In January 2022, Merck KGaA acquired CDMO Exelead, a pharmatech company. The agreement added value to Merck KGaA’s lipid nanoparticle and mRNA capabilities.
In May 2021, Bio-Techne Corporation and 908 Devices announced a collaboration to develop an extended workflow solution for protein characterization with the help of the ZipChip device. Vascular Endothelial Growth Factor Industry Report Scope
Key Segments Covered in VEGF Industry Survey
Vascular Endothelial Growth Factor (VEGF) Market by VEGF Type:
- Human VEGF
- Mouse VEGF
- Rat VEGF
- Rabbit VEGF
- Others VEGF
Vascular Endothelial Growth Factor (VEGF) Market by Expression Host:
- CHO
- Coli
- HEK
- NSO
- Insect Cells
- Others
Vascular Endothelial Growth Factor (VEGF) Market by Application:
- Cell Culture
- Cell-based Therapy
- Drug Development
- Gene Therapy
- Rare Disease treatment
- Wound Healing Research
- Combination Therapies
- Hematology Research
- Osteogenesis
- Anti-Angiogenic Therapy
Vascular Endothelial Growth Factor (VEGF) Market by End User:
- Pharmaceutical & Biotechnology Companies
- Academic Institutes
- CMOs & CDMOs
- Other End Users
- Research Centers & Laboratories
- Hospital-attached Laboratories (HALs)
Vascular Endothelial Growth Factor (VEGF) Market by Region:
- North America VEGF Market
- Latin America VEGF Market
- Europe VEGF Market
- South Asia VEGF Market
- East Asia VEGF Market
- Oceania VEGF Market
- Middle East & Africa VEGF Market
Buy Now this Report@ https://www.persistencemarketresearch.com/checkout/33129
About Us
Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.
Contact Us
Persistence market research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – [email protected]